Pre-emptive antinociceptive effects of a synthetic cannabinoid in a model of neuropathic pain
Authors:
- Julie DesrochesJDJulie Desroches
- Mélina DaniMDMélina Dani
- Pierre BeaulieuPBPierre Beaulieu
- 1 July 2007
- journal article
- research article
- Published by Elsevier in European Journal of Pharmacology
- Vol. 568 (1-3) , 173-176
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Antinociceptive effect of cannabinoid agonist WIN 55,212-2 in rats with a spinal cord injuryExperimental Neurology, 2007
- Anandamide mediates hyperdynamic circulation in cirrhotic rats via CB1 and VR1 receptorsBritish Journal of Pharmacology, 2006
- Antihyperalgesic effects of local injections of anandamide, ibuprofen, rofecoxib and their combinations in a model of neuropathic painNeuropharmacology, 2006
- Cannabinoid CB2 receptor agonist activity in the hindpaw incisionEuropean Journal of Pharmacology, 2005
- Repeated treatment with the synthetic cannabinoid WIN 55,212‐2 reduces both hyperalgesia and production of pronociceptive mediators in a rat model of neuropathic painBritish Journal of Pharmacology, 2004
- Upregulation of spinal cannabinoid-1-receptors following nerve injury enhances the effects of Win 55,212-2 on neuropathic pain behaviors in ratsPain, 2003
- Localisation of cannabinoid receptor 1 in rat dorsal root ganglion using in situ hybridisation and immunohistochemistryNeuroscience, 2003
- The synthetic cannabinoid WIN55,212‐2 attenuates hyperalgesia and allodynia in a rat model of neuropathic painBritish Journal of Pharmacology, 2001
- The analgesic effects of R(+)-WIN 55,212–2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic painNeuroscience Letters, 1997
- A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesiaPain, 1988